Scientists Turn One Stem Cell Into 14 Million Cancer-Fighting NK Cells
Chinese researchers developed a breakthrough method to mass-produce powerful immune cells that hunt and destroy cancer tumors.
20 articles
Chinese researchers developed a breakthrough method to mass-produce powerful immune cells that hunt and destroy cancer tumors.
New trial data reveals AstraZeneca's experimental in vivo CAR-T therapy showed early responses in multiple myeloma patients but resulted in one death.
Australian biotech company creates targeted treatment that attacks malignant plasma cells while sparing healthy ones in multiple myeloma patients.
McGill scientists boosted NK cell cancer-killing power using reversible drug treatment, targeting leukemia, glioblastoma, and triple-negative breast cancer.
Key biotech companies developing T cell engager therapies that redirect immune cells to fight cancer more effectively.
New research reveals senescent cells have both harmful and protective roles, pushing anti-aging science toward targeted removal strategies.
Revolutionary CRISPR technique bypasses lab manufacturing by programming immune cells to fight cancer directly in the body.
Redesigned immunotherapy injected into one tumor triggered complete cancer remission in 2 of 12 patients, with untreated tumors also disappearing.
A newly identified molecule called SLAMF6 exhausts cancer-fighting T cells from within โ and blocking it may revive failed immunotherapies.
Scientists found drugs that kill senescent 'zombie cells' by blocking their key survival protein, shrinking tumors in mice.
Single injection of engineered virus kills glioblastoma cells and activates immune system, extending patient survival in clinical trial.
New biotech innovations are advancing prostate cancer therapy with promising approaches for better patient outcomes.
Scientists discover D-cysteine selectively targets cancer cells by disrupting their energy production without harming normal cells.
A new imaging breakthrough reveals how immune cells target cancer with nanoscale precision, opening doors for better immunotherapy.
A short pre-surgery course of pembrolizumab left zero relapses in colorectal cancer patients after 33 months โ reshaping treatment strategy.
A protein called HOXD13 drives skin cancer growth and shields tumors from immune cells โ disabling it could unlock powerful new treatments.
Disabling the NFIL3 protein prevents CAR T cell exhaustion, boosting tumor-fighting power in animal models of hard-to-treat cancers.
When tumors hide from killer T cells, they accidentally expose themselves to helper T cells that trigger a lethal iron-driven cell death process.
MYC protein doesn't just fuel tumor growth โ it also repairs DNA damage from chemotherapy, revealing a key resistance mechanism.
New research reveals how tumors reprogram neutrophils to produce CCL3, turning immune defenders into cancer allies.